A friend asked Huazi, saw the notification of the State Food and Drug Administration, independently developed by China, with independent intellectual property rights to treat diabetes new drugs, siglitaz sodium listed, what type of hypoglycemic drug is this?
Siglitaz sodium is the world's first peroxidase proliferative receptor (PPAR) total agonist, Huazi said. If you look at the pharmacological effect, siglitazate has similarities with insulin sensitizer thiazolidinedione (TZD) drugs, but the effect is more comprehensive. Not only can blood sugar be lowered, but also blood lipids can be regulated, and side effects are also lower.
<h1 class="pgc-h-arrow-right" data-track="3" >, many diabetics are not short of insulin</h1>
In the impression of many people, suffering from diabetes is that the body secretes less insulin. But many type 2 diabetic patients, the body can normally secrete insulin, but the sensitivity of the tissue cells in the body to insulin decreases, that is, insulin resistance occurs, and the use of blood glucose decreases, which leads to an increase in blood sugar.
The most common cause of insulin resistance is obesity, and some obese type 2 diabetics, even if they inject insulin, have a very limited hypoglycemic effect. However, after taking diet control and enhancing exercise to reduce weight, oral medication alone can control blood sugar very well.
<h1 class="pgc-h-arrow-right" data-track="18" > second, drugs that reduce insulin resistance</h1>
However, some people with type 2 diabetes, after diet control and increased exercise, still cannot reduce insulin resistance, and need to use drugs to improve symptoms. Commonly used drugs to reduce insulin resistance are metformin (but less effective) and thiazolidinediones (TZD) drugs (rosiglitazone, pioglitazone).
The effect of TZD drugs can stimulate the γ receptors in PPAR, improve the body's sensitivity to insulin, and reduce appetite. However, TZD drugs have more adverse reactions, which can lead to weight gain when used, may lead to hypoglycemia when combined with other hypoglycemic drugs, and may aggravate heart failure, rosiglitazone may cause liver damage, pioglitazone may increase the incidence of bladder cancer, and the use of more restrictions.
<h1 class="pgc-h-arrow-right" data-track="19" > third, siglita sodium can lower sugar and lipids</h1>
There are three subtypes of peroxisome proliferative receptors (PPAR), namely α, δ, and γ. Among them, PPAR-γ receptors are associated with blood glucose regulation, while PPAR-α, PPAR-δ receptors are associated with lipid regulation.
China's independent research and development of siglitazole sodium, is the world's first marketed PPAR total agonist, on the α, δ, γ three subtypes will have an inflammatory effect, not only can reduce blood sugar, but also regulate blood lipids.
In the phase III clinical trial, siglitazate can reduce glycosylated hemoglobin (HbA1c) by 1.32% to 1.52%, which will have a good control effect on fasting blood glucose, postprandial blood glucose, insulin resistance index, triglycerides, free fatty acids, etc.
<h1 class="pgc-h-arrow-right" data-track="20" >4, siglitazine has fewer side effects</h1>
In terms of drug safety, sigliglig sodium has an activating effect on the three subtypes of PPAR α, δ, γ, which can balance the glycolipid regulatory effects of the three subtypes and avoid the potential side effects brought about by a single activation γ subtype. In terms of common side effects such as edema and weight gain, siglitazal is significantly lower than that of traditional TZD drugs.
In multicenter, randomized, double-blind controlled clinical trials, siglitazole sodium triggered adverse effects comparable to those in the placebo group. That is to say, while playing a hypoglycemic and lipid-regulating role, siglitazate does not lead to an increase in adverse reactions, and the safety is very good.
To summarize, insulin resistance is a common cause of type 2 diabetes, and improving insulin resistance is a core need to treat type 2 diabetes. However, traditional TZD drugs have greater side effects and limit their application. China's independent research and development of siglitazole sodium can not only reduce glucose, but also regulate blood lipids, and the side effects are low, the safety is very good, bringing more choices to the treatment of type 2 diabetes.
Medications should be used under the guidance of a doctor, and if you have any doubts about medication, please consult a doctor or pharmacist. I am a pharmacist Huazi, welcome to follow me and share more health knowledge.